181 related articles for article (PubMed ID: 20078106)
1. Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
de la Fuente T; Martín-Fontecha M; Sallander J; Benhamú B; Campillo M; Medina RA; Pellissier LP; Claeysen S; Dumuis A; Pardo L; López-Rodríguez ML
J Med Chem; 2010 Feb; 53(3):1357-69. PubMed ID: 20078106
[TBL] [Abstract][Full Text] [Related]
2. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
[TBL] [Abstract][Full Text] [Related]
3. Novel quinazolinone derivatives as 5-HT7 receptor ligands.
Na YH; Hong SH; Lee JH; Park WK; Baek DJ; Koh HY; Cho YS; Choo H; Pae AN
Bioorg Med Chem; 2008 Mar; 16(5):2570-8. PubMed ID: 18083580
[TBL] [Abstract][Full Text] [Related]
4. Benzimidazole derivatives. Part 5: design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands.
López-Rodríguez ML; Benhamú B; Morcillo MJ; Tejada I; Avila D; Marco I; Schiapparelli L; Frechilla D; Del Río J
Bioorg Med Chem; 2004 Oct; 12(19):5181-91. PubMed ID: 15351401
[TBL] [Abstract][Full Text] [Related]
5. New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
Hinschberger A; Butt S; Lelong V; Boulouard M; Dumuis A; Dauphin F; Bureau R; Pfeiffer B; Renard P; Rault S
J Med Chem; 2003 Jan; 46(1):138-47. PubMed ID: 12502367
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
López-Rodríguez ML; Porras E; Morcillo MJ; Benhamú B; Soto LJ; Lavandera JL; Ramos JA; Olivella M; Campillo M; Pardo L
J Med Chem; 2003 Dec; 46(26):5638-50. PubMed ID: 14667218
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and serotonergic activity of substituted 2, N-benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N, N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT(1B)-like receptor.
Moloney GP; Martin GR; Mathews N; Milne A; Hobbs H; Dodsworth S; Sang PY; Knight C; Williams M; Maxwell M; Glen RC
J Med Chem; 1999 Jul; 42(14):2504-26. PubMed ID: 10411472
[TBL] [Abstract][Full Text] [Related]
8. Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition of 5-HT(4) receptor antagonists.
López-Rodríguez ML; Murcia M; Benhamú B; Viso A; Campillo M; Pardo L
J Med Chem; 2002 Oct; 45(22):4806-15. PubMed ID: 12383006
[TBL] [Abstract][Full Text] [Related]
9. Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor.
Purohit A; Herrick-Davis K; Teitler M
Synapse; 2003 Mar; 47(3):218-24. PubMed ID: 12494404
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
[TBL] [Abstract][Full Text] [Related]
11. Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
Lemaître S; Lepailleur A; Bureau R; Butt-Gueulle S; Lelong-Boulouard V; Duchatelle P; Boulouard M; Dumuis A; Daveu C; Lezoualc'h F; Pfeiffer B; Dauphin F; Rault S
Bioorg Med Chem; 2009 Mar; 17(6):2607-22. PubMed ID: 19261477
[TBL] [Abstract][Full Text] [Related]
12. Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.
Elokdah H; Li D; McFarlane G; Bernotas RC; Robichaud AJ; Magolda RL; Zhang GM; Smith D; Schechter LE
Bioorg Med Chem; 2007 Sep; 15(18):6208-26. PubMed ID: 17624788
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors.
Berque-Bestel I; Soulier JL; Giner M; Rivail L; Langlois M; Sicsic S
J Med Chem; 2003 Jun; 46(13):2606-20. PubMed ID: 12801225
[TBL] [Abstract][Full Text] [Related]
14. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists.
López-Rodríguez ML; Benhamú B; de la Fuente T; Sanz A; Pardo L; Campillo M
J Med Chem; 2005 Jun; 48(13):4216-9. PubMed ID: 15974573
[TBL] [Abstract][Full Text] [Related]
15. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
Orjales A; Mosquera R; Labeaga L; Rodes R
J Med Chem; 1997 Feb; 40(4):586-93. PubMed ID: 9046349
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
17. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
[TBL] [Abstract][Full Text] [Related]
18. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling.
Hirst WD; Abrahamsen B; Blaney FE; Calver AR; Aloj L; Price GW; Medhurst AD
Mol Pharmacol; 2003 Dec; 64(6):1295-308. PubMed ID: 14645659
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.
Hayat F; Cho S; Rhim H; Indu Viswanath AN; Pae AN; Lee JY; Choo DJ; Choo HY
Bioorg Med Chem; 2013 Sep; 21(17):5573-82. PubMed ID: 23810425
[TBL] [Abstract][Full Text] [Related]
20. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor.
Brüss M; Kiel S; Bönisch H; Kostanian A; Göthert M
Neurochem Int; 2005 Aug; 47(3):196-203. PubMed ID: 15896881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
